Details of the primary studies for muscle strength and activation
Study | Treatment | Biofeedback mode | EMG device | Outcome parameter | Outcome values | ES | |
---|---|---|---|---|---|---|---|
EMG FB Group | Control Group | ||||||
[16] | 8 weeks (daily)
| Visual
| Myomed 134 | EMG onset | Pre:562.09 ± 55.33Post:487.92 ± 46.71 | Pre:548.21 ± 64.76Post:538.41 ± 53.58 | 1.01* |
EMG offset | Pre:687.54 ± 75.39Post:570.17 ± 62. 11 | Pre:701.23 ± 69.52Post:682.31 ± 65.68 | 1.76* | ||||
Knee flexor strength | Pre:38.23 ± 11.03Post:84.02 ± 6.95 | Pre:37.42 ± 10.48Post:86.04 ± 5.43 | 0.32 | ||||
Knee extensor strength | Pre:41.75 ± 10.54Post:87. 11 ± 6.54 | Pre:42.92 ± 12.49Post:86.39 ± 6.74 | 0.11 | ||||
[17] | 8 weeks (12 × 15 min sessions)
| Visual & acoustic
| MyoTrac Infiniti | Electrical activity VM | Pre:207.7 ± 86.7Post:342. 1 ± 108.5 | Pre:223.0 ± 82. 1Post:347.3 ± 86.0 | 0.05 |
[18] | 3 weeks (3 times every day)
| Visual & acoustic
| Myomed 932 | Knee extension strength 60°/s | Pre:47.84 ± 17.87Post:54.47 ± 17.97 | Pre:50.25 ± 24.2Post:62.95 ± 22.8 | 0.41 |
Knee flexion strength 60°/s | Pre:32.94 ± 14.38Post:42.26 ± 23.94 | Pre:27.75 ± 18.9Post:40.6 ± 19.79 | 0.08 | ||||
Knee extension strength 180°/s | Pre:23.68 ± 7.31Post:31.89 ± 9.28 | Pre:24.85 ± 11. 1Post:35.55 ± 12.6 | 0.33 | ||||
Knee extension strength 180°/s | Pre:17.10 ± 12.95Post:24.10 ± 13.87 | Pre:13.85 ± 11.4Post:22.95 ± 15.5 | 0.08 | ||||
Knee isometric extension strength | Pre:77.94 ± 28.47Post:103.57 ± 63. 1 | Pre:79.3 ± 26.61Post:83.35 ± 21.4 | 0.43 | ||||
[20] | 6 weeks (3 times per week)
| Visual & acoustic
| NeuroTrac MyoPlus4 Pro | Shoulder flexion strength | Pre:65.00 ± 20.16Post:78.20 ± 22.87 | Pre:70.55 ± 24. 11Post:74.74 ± 23.54 | 0.15* |
[21] | 8 weeks (3 times per week)
| Visual
| Myomed 932 | Activation capacity TA | Pre:17.69 ± 2.23Post:35.09 ± 1.31 | Pre:17.59 ± 2.49Post:33.60 ± 2.2 | 0.82* |
[19] | 4 weeks (2 times per week)
| Visual
| mDurance system | RMS SPlimb affected | Pre:100. 1 ± 13. 1Post:171.5 ± 5.1 | Pre:101.2 ± 11.9Post:145. 1 ± 12.9 | 2.72* |
RMS SPlimb free | Pre:172.3 ± 6.0Post:182.5 ± 5.2 | Pre:170.9 ± 4.8Post:182.6 ± 8.7 | 0.01 | ||||
[15] | 5 weeks (5 times per week)
| Visual
| Myomed 932 | Knee isometric extension strength | Pre:9.07 ± 1.87Post:13.68 ± 1.99 | Pre:9.42 ± 1.86Post:11.06 ± 1.56 | 1.47* |
[22] | 5 weeks (2 times per week)
| Visual & acoustic
| Ouroboros EMG-1821 | IEMG activity QM | Pre:442.95 ± 95.65Post:525.90 ± 112.20 | Pre:407.34 ± 40.81Post:454.97 ± 53.20 | 0.81* |
Knee extension peak torque | Pre:165.28 ± 30.10Post:234.28 ± 52.63 | Pre:165.85 ± 37.08Post:211.57 ± 40.57 | 0.48* | ||||
[23] | 19 days (5 times per week)
| Visual
| Cyborg J-33 | Knee extension peak torque trained leg | Pre:113.26 ± 37.01Post:138.59 ± 19.38 | Pre:103.73 ± 25.07Post:103.23 ± 27.50 | 1.49* |
Knee extension peak torque untrained leg | Pre:114.04 ± 35.27Post:127.78 ± 32.92 | Pre:97.60 ± 22.46Post:95.57 ± 17.52 | 1.22* |
* Significant effects between EMG FB Group and Control Group post intervention. ES: effect size; VL: vastus lateralis muscle; VM: vastus medialis muscle; BF: biceps femoris muscle; SM: semimembranosus muscle; AD: anterior deltoid muscle; RA: rectus abdominis muscle; SP: supraspinatus muscle; RF: rectus femoris muscle; TA: transversus abdominis muscle; QM: quadriceps femoris muscle; IEMG: integrated electromyography; RMS: root mean square